GeNeuro SA
GNRO
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,360.00 | 19.00 | 0.23% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,669.36 | 141.74 | 0.35% |
| FTSE 100 | 8,494.85 | 31.39 | 0.37% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,446.34 | 14.98 | -0.09% |
| Nikkei 225 | 36,241.70 | 196.32 | 0.54% |
| NZX 50 Index | 12,021.14 | 117.83 | 0.99% |
| S&P 500 | 5,569.06 | 8.23 | 0.15% |
| S&P/ASX 200 | 8,143.20 | 17.00 | 0.21% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |